Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

beam

beam is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 1
Pipeline programs 13
News articles 0
Drug details — beam
Class
—
Route
—
Patents
1
Programs
13
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

beam is an FDA-listed pharmaceutical active ingredient.

Key facts

INN beam

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. BEAM-101 Phase 2 · Beam Therapeutics · Sickle Cell Disease
  2. BEAM-201 Phase 2 · Beam Therapeutics · Lymphoblastic Lymphoma
  3. BEAM-301: Single dose of BEAM-301 administered by IV Phase 2 · Beam Therapeutics · Glycogen Storage Disease Type Ia
  4. BEAM-302 Phase 2 · Beam Therapeutics · Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Diseas
  5. BEAM-302 Phase 2 · Beam Therapeutics · Alpha 1-Antitrypsin Deficiency
  6. Bedaquiline (B) Phase 2 · Chinese Academy of · Tuberculosis, Pulmonary
  7. 1479-0001 Phase 1 · Boehringer Ingelheim · Solid tumours with HER2 aberrations, Non-small cell lung can
  8. Allogeneic anti-CD7 CAR-T cells (BEAM-201) Phase 1 · Beam Therapeutics · T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Related patents

Browse patents

  1. US 11202152

    Acoustic beamforming

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is beam?

beam is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.